Strategic partnerships Aptevo is actively pursuing radiopharmaceutical collaborations, including a 50/50 joint initiative with Niowave to develop up to three radiopharmaceutical oncology programs, presenting a clear entry point for co-development discussions and technology licensing opportunities.

Pipeline expansion The company is advancing mipletamig in phase 1b with regulatory engagement planned, and pursuing radiation-targeted therapies across solid tumors, offering multiple near-term collaboration or in-licensing opportunities with companies seeking new IO candidates or radiopharmaceutical platforms.

Platform leverage APTO leverages the proprietary ADAPTIR and ADAPTIR-FLEX platforms for immuno-oncology, suggesting potential for parallel partnerships in companion diagnostics, analytics, or platform-based co-development with biotech and pharma players seeking scalable IO modalities.

Leadership and talent Recent executive appointment of a new Chief Scientific Officer and ongoing board leadership changes indicate a strategic shift and growth trajectory, creating opportunities for advisory, consulting, or executive-level engagement with potential aligned sponsors or investors.

Clinical and regulatory readiness With clinical-stage status, ongoing phase initiatives, and a Seattle-based innovation culture, there is potential to engage around grant-supported trials, accelerated regulatory pathways, and translational collaboration with contract research organizations and academic partners.